Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 13, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details changes in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan"):
- March 2, 2006: Holdings decreased from 17,746,383 to 17,673,360 ADRs at an average price of $51.10.
- March 9, 2006: Holdings decreased from 17,673,360 to 17,518,760 ADRs at an average price of $51.65.
These movements were driven by fund activity and notified to the company on March 13 and March 10, 2006, respectively.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the Plan is a discretionary fund for current and former employees, and that Directors Dr. J P Garnier and Dr. T Yamada are potentially interested in the shares held in the fund in the same manner as other employees.
Investor Verification Points
- Verify the total reduction in ADR holdings by the US Retirement Savings Plan over the reported period.
- Confirm the average transaction prices ($51.10 and $51.65) against market data for the respective dates.
- Note that the reported changes reflect fund movements rather than direct discretionary trading by the named directors.